Comparative Pharmacology
Head-to-head clinical analysis: MIOCHOL E versus MIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIOCHOL E versus MIOSTAT.
MIOCHOL-E vs MIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholinergic agonist: mimics acetylcholine at muscarinic receptors, causing contraction of the sphincter muscle of the iris (miosis) and ciliary muscle (accommodation).
MIOSTAT (carbachol intraocular solution) is a cholinergic agent that mimics the effects of acetylcholine, causing miosis (pupil constriction) by stimulating muscarinic receptors on the sphincter muscle of the iris.
Intracameral injection: 0.5 mL of reconstituted solution (containing 1:100 acetylcholine chloride) instilled into the anterior chamber of the eye after lens delivery and before wound closure. Single dose per procedure; repeat if necessary, but not within 24 hours.
Intracameral injection of 0.01 mg (0.5 mL of 0.02 mg/mL solution) as a single dose during surgery.
None Documented
None Documented
Terminal elimination half-life of acetylcholine is approximately 1-2 minutes due to rapid hydrolysis by acetylcholinesterase; in the eye, the miotic effect lasts about 4-6 hours.
Intraocular half-life approximately 1-2 hours; systemic half-life negligible due to rapid metabolism.
Renal (primarily as unchanged drug and metabolites via glomerular filtration and tubular secretion) ~90%; fecal ~10%.
Primarily via intraocular metabolism; systemic absorption minimal. No significant renal or biliary excretion.
Category C
Category C
Ophthalmic Miotic
Ophthalmic Miotic